--- title: "Insider Selling: Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells 7,400 Shares of Stock" type: "News" locale: "en" url: "https://longbridge.com/en/news/291657721.md" description: "Cadrenal Therapeutics CEO Quang Pham sold 7,400 shares on June 29 at an average price of $3.03, totaling approximately $22,422. Executed under a Rule 10b5-1 plan, the sale reduced his holdings by 6.98%, leaving him with 98,589 shares valued at roughly $298,725. The transaction was disclosed via SEC filing." datetime: "2026-07-03T10:53:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291657721.md) - [en](https://longbridge.com/en/news/291657721.md) - [zh-HK](https://longbridge.com/zh-HK/news/291657721.md) generator: "portal-rs" --- # Insider Selling: Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells 7,400 Shares of Stock ## Key Points - **Cadrenal Therapeutics CEO Quang Pham sold 7,400 shares** on June 29 at an average price of $3.03, totaling about $22,422. The sale reduced his holdings by 6.98% and was made under a pre-arranged Rule 10b5-1 trading plan. - **The stock has been under pressure**, opening at $3.60 and trading well below its 50-day and 200-day moving averages. It also sits far off its 52-week high of $14.64, with a market cap of about $10.33 million. - **Recent fundamentals and sentiment are mixed**: Cadrenal beat quarterly EPS estimates, but analysts still have a cautious overall view with a consensus **Hold** rating and a $13 price target. Institutional ownership remains relatively modest at 7.92%. Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) CEO Quang Pham sold 7,400 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $3.03, for a total value of $22,422.00. Following the transaction, the chief executive officer owned 98,589 shares of the company's stock, valued at $298,724.67. The trade was a 6.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. ## Cadrenal Therapeutics Stock Performance Shares of Cadrenal Therapeutics stock opened at $3.60 on Friday. Cadrenal Therapeutics, Inc. has a 52-week low of $2.55 and a 52-week high of $14.64. The stock's 50-day simple moving average is $4.57 and its 200 day simple moving average is $5.98. The stock has a market capitalization of $10.33 million, a P/E ratio of -0.64 and a beta of 1.73. Cadrenal Therapeutics (NASDAQ:CVKD - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, beating the consensus estimate of ($1.51) by $0.47. Equities research analysts forecast that Cadrenal Therapeutics, Inc. will post -5.52 EPS for the current fiscal year. ## Analyst Ratings Changes * * * * * * CVKD has been the subject of several analyst reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Cadrenal Therapeutics in a report on Monday, April 20th. HC Wainwright lowered their target price on shares of Cadrenal Therapeutics from $32.00 to $13.00 and set a "buy" rating on the stock in a report on Tuesday, April 7th. Finally, Wall Street Zen upgraded Cadrenal Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Cadrenal Therapeutics has a consensus rating of "Hold" and a consensus price target of $13.00. **Get Our Latest Analysis on Cadrenal Therapeutics** ## Institutional Inflows and Outflows Several large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new stake in shares of Cadrenal Therapeutics during the third quarter valued at about $103,000. Geode Capital Management LLC lifted its holdings in shares of Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company's stock worth $98,000 after buying an additional 1,818 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Cadrenal Therapeutics in the third quarter valued at approximately $274,000. Finally, DRW Securities LLC bought a new position in shares of Cadrenal Therapeutics in the fourth quarter valued at approximately $171,000. Institutional investors own 7.92% of the company's stock. ## Cadrenal Therapeutics Company Profile (Get Free Report) Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. ## Featured Articles - Five stocks we like better than Cadrenal Therapeutics - Shorting the Grid: Bloom Energy’s $25B AI Power Play - SanDisk’s Volatility May Be Telling Bulls What They Want to Hear - Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon - 3 Dividend ETFs Built for Stability in a Volatile Market *This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to \[email protected\].* Insider Buying or Selling at Cadrenal Therapeutics? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Cadrenal Therapeutics and related companies. From Our Partners Trump Takes Emergency Action - Plus Elon Musk's New Venture Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru... Altimetry Do NOT Buy SpaceX – Do This Instead SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul... Stansberry Research SPCX Warning - and Worst News for Stocks in 50 Years Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ... TradeSmith CODE RED: AI Meltdown Imminent? After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri... Paradigm Press Trump just signed it A recent policy development is drawing attention from income-focused investors. According to one analyst, c... Investors Alley From the man who predicted 2008 crash… Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the... Porter & Company Your $29.97 book is free today Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca... Profits Run Better than SpaceX? Grab this ticker instead. Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says... Brownstone Research ### Related Stocks - [CVKD.US](https://longbridge.com/en/quote/CVKD.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [BE.US](https://longbridge.com/en/quote/BE.US.md) - [SNDK.US](https://longbridge.com/en/quote/SNDK.US.md) - [META.US](https://longbridge.com/en/quote/META.US.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) ## Related News & Research - [Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells 3,613 Shares](https://longbridge.com/en/news/290289189.md) - [Cadrenal Therapeutics CEO, Chairman Quang X. Pham disposes of 7,400 common shares worth $22,422](https://longbridge.com/en/news/291482268.md) - [Mark Brosius Sells 77 Shares of Intuitive Surgical (NASDAQ:ISRG) Stock](https://longbridge.com/en/news/296661262.md) - [Insider Selling: Gloo (NASDAQ:GLOO) Major Shareholder Sells 4,000 Shares of Stock](https://longbridge.com/en/news/296410780.md) - [Mercury Systems (NASDAQ:MRCY) EVP Steven Ratner Sells 2,187 Shares](https://longbridge.com/en/news/296653562.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**